三种鼠尾草注射液对大鼠心肌缺血再灌注损伤的保护作用

本文研究了云南产鼠尾草属药物滇丹参、甘西鼠尾、褐毛甘西鼠尾对急性心肌缺血再灌注损伤的保护作用 ,并与丹参进行对比其疗效的相似性。结扎大鼠冠脉左前降支 ,30分钟后剪断结扎线造成心肌缺血再灌注模型 ,经股静脉给药。测定再灌注 6 0分钟后血清中CK、LDH、SOD、GSH -Px和MDA含量。结果滇丹参、甘西鼠尾、褐毛甘西鼠尾可以显著降低心肌缺血再灌注后血清CK、LDH和MDA含量 ,升高血清SOD和GSH -Px活力 (P <0 0 1,P <0 0 5 ) ,与丹参有相似的抗心肌缺血再灌注损伤作用。     

两种滇产鼠尾草复方注射液对大鼠在体心肌缺血再灌注损伤的保护作用

与复方丹参注射液（丹参＋三七）比较,探讨两种滇产鼠尾草复方注射液。即复方滇丹参（滇丹参＋三七）和复方甘西鼠尾（甘西鼠尾＋三七）对大鼠在体心肌缺血再灌注损伤的保护作用。采用在体缺血再灌注模型,缺血30min复灌60min。实验过程中用II导联记录心电图ST段和心率变化,实验后测定心室梗塞面积。结果：这两种复方鼠尾草注射液能显著降低在体心肌缺血和再灌注过程中ST段抬高水平。轻度加快缺血再灌注过程心率,相似于复方丹参;这两种鼠尾草复方注射液均能明显减少心室梗塞面积。这两种滇产鼠尾草复方注射液均有较好的抗心肌缺血再灌注损伤作用,与复方丹参注射液相似。     

褐毛甘西鼠尾注射液对大鼠在体心肌缺血再灌注损伤的保护作用

本实验与丹参进行对比研究云南产鼠尾草属药物褐毛甘西鼠尾对急性心肌缺血再灌注损伤的保护作用。采用结扎大鼠冠脉左前降支方法造成心肌缺血再灌注模型,测定再灌注60 min后血清中CK、LDH、SOD、GSH-Px和MDA含量。实验结果显示:该药可以显著降低心肌缺血再灌注后血清CK、LDH和MDA含量,升高血清SOD和GSH-Px活力(P<0.01,P<0.05)。表明褐毛甘西鼠尾对在体缺血/再灌注心肌有保护作用。     

滇丹参、甘西鼠尾、褐毛甘西鼠尾水提取液对鼠血栓形成及微循环的影响

目的：观察云南产甘西鼠尾属药物滇丹参、甘西鼠尾、褐毛甘西鼠尾的水提取物对鼠血栓形成及微循环的影响。方法：用电刺激法造成大鼠颈动脉血栓形成,观察血流阻塞时间(OT值);小鼠尾静脉注射血栓形成诱导剂,观察滇丹参、甘西鼠尾、褐毛甘西鼠尾对抗肺血栓形成的作用;采用活体微循环观察方法,研究滇丹参、甘西鼠尾、褐毛甘西鼠尾对去甲肾上腺素和高分子右旋糖苷所致小鼠、大鼠肠系膜微循环障碍的影响。结果：滇丹参、甘西鼠尾、褐毛甘西鼠尾2、4g/kg时,能明显延长闭塞性血栓形成时间(OT值)(P＜0．01)。20、40g/kg时,能有效抑制胶原和肾上腺素复合液所致小鼠肺血栓形成(P＜0．0l,P＜0．05)。能显著改善微动脉、微静脉痉挛和血液流态,增加毛细血管开放数,加快血流速度(P＜0．0l,P＜0．05)。结论：滇丹参、甘西鼠尾、褐毛甘西鼠尾均能防止血栓形成、改善微循环障碍。     

黄芪皂苷IV对心肌缺血／再灌注损伤的保护及抗凋亡作用的研究

目的：探讨黄芪皂苷Ⅳ对大鼠心肌缺血／再灌注损伤的保护作用及抗凋亡作用。方法：研究黄芪皂苷Ⅳ对大鼠收缩压和舒张压的作用;建立大鼠心肌缺血／再灌注模型,在缺血前给予黄芪皂苷Ⅳ处理,观察心律失常的改变,测定血液中乳酸脱氢酶（LDH）、超氧化物歧化酶（SOD）和丙二醛（MDA）的变化,检测计算凋亡心肌细胞百分比及对P-STAT1、P-STAT3蛋白表达的调控作用。结果：黄芪皂苷Ⅳ可降低大鼠收缩压和舒张压,心肌缺血／再灌注前,预先给予黄芪皂苷Ⅳ有抗心律失常作用,降低血液中LDH和MDA含量,提高SOD活性,降低凋亡心肌细胞百分比,显著增加P-STAT1蛋白表达而同时降低P-STAT3蛋白表达。结论：黄芪皂苷Ⅳ对心肌缺血／再灌注损伤具有一定的保护作用,减少心肌细胞凋亡,其机制可能与抑制P—STAT1,诱导P—STAT3表达有关。     

三七皂苷对缺氧复氧心肌细胞损伤保护作用的研究

目的：研究三七皂苷对纯化培养大鼠乳鼠心肌细胞缺氧/复氧损伤的保护作用及机制。方法：采用纯化培养的心肌细胞建立缺氧/复氧损伤模型,测定细胞凋亡率、caspase-3、乳酸脱氢酶（LDH）、丙二醛（MDA）、超氧化物歧化酶（SOD）含量。结果：与正常组比较,模型组LDH、MDA含量、caspase-3活性及细胞凋亡率明显升高（P＆lt;0.01）,SOD活性明显降低（P＆lt;0.01）;三七皂苷组降低LDH、MDA含量、caspase-3活性和细胞凋亡率,提高SOD活性,与缺氧/复氧组比较各实验指标差异均具有显著性（P＆lt;0.05）。结论：三七皂苷对缺氧/复氧心肌细胞损伤有保护作用,作用机制与清除氧自由基,抗脂质过氧化及降低细胞凋亡率有关。     

2类多巴胺受体对心肌缺血后处理保护作用的影响及机制

目的：观察2类多巴胺受体（DR2）在心肌缺血后处理保护中的作用,并探讨其机制。方法：复制原代培养乳鼠心肌细胞缺血后处理模型,细胞随机分为正常组（Control）、缺血/再灌注组（I/R）、缺血后处理组（PC）、缺血后处理＋DR2激动剂组（PC＋Bro）、缺血后处理＋DR2抑制剂组（PC＋Hal）、缺血后处理＋DR2抑制剂＋激动剂组（PC＋Hal＋Bro）。比色法检测细胞培养液乳酸脱氢酶（LDH）、超氧化物歧化酶（SOD）活性和丙二醛（MDA）含量;透射电镜观察细胞超微结构改变;流式细胞仪检测细胞凋亡变化;Western blot方法检测DR2蛋白表达、p-p38和p-JNK的活性。结果：与正常组相比,I/R能够增加DR2蛋白的表达,升高LDH活性和MDA含量,降低SOD活性,加重细胞损伤和细胞凋亡,上调p-p38和p-JNK的活性;与I/R组比较,PC进一步增加DR2蛋白的表达,降低LDH活性和MDA含量,增加SOD活性,减轻细胞损伤和细胞凋亡,下调p-p38和p-JNK的活性,Bro增强了PC的心肌保护作用,Hal则可取消Bro的这种作用。结论：DR2激活通过下调p-p38和p-JNK的活性参与缺血后处理对心肌缺血/再灌注损伤的保护作用。     

黄芪皂苷Ⅳ对心肌缺血/再灌注损伤的保护及抗凋亡作用的研究

目的:探讨黄芪皂苷Ⅳ对大鼠心肌缺血/再灌注损伤的保护作用及抗凋亡作用。方法:研究黄芪皂苷Ⅳ对大鼠收缩压和舒张压的作用;建立大鼠心肌缺血/再灌注模型,在缺血前给予黄芪皂苷Ⅳ处理,观察心律失常的改变,测定血液中乳酸脱氢酶(LDH)、超氧化物歧化酶(SOD)和丙二醛(MDA)的变化,检测计算凋亡心肌细胞百分比及对P-STAT1、P-STAT3蛋白表达的调控作用。结果:黄芪皂苷Ⅳ可降低大鼠收缩压和舒张压,心肌缺血/再灌注前,预先给予黄芪皂苷Ⅳ有抗心律失常作用,降低血液中LDH和MDA含量,提高SOD活性,降低凋亡心肌细胞百分比,显著增加P-STAT1蛋白表达而同时降低P-STAT3蛋白表达。结论:黄芪皂苷Ⅳ对心肌缺血/再灌注损伤具有一定的保护作用,减少心肌细胞凋亡,其机制可能与抑制P-STAT1,诱导P-STAT3表达有关。     

雷米普利与BQ-123合用对大鼠在体心肌缺血／再灌注损伤的保护作用

目的：研究雷米普利与BQ-123合用对大鼠在体心肌缺血／再灌注损伤的影响。方法：健康雄性Wistar大鼠随机分为5组,制备缺血30min再灌注120min模型,采用雷米普利、BQ-123单用及两药联合应用的方式处理实验动物。观察两药合用对大鼠在体心肌缺血／再灌注损伤的保护作用。观察动物心率、血压、心电图ST-段变化,记录缺血期室性心律失常;检测血浆CK及LDH活力;心肌HE染色和TIC染色,定性和定量检测心肌梗死情况。结果：与I／R组比较,各给药组ST-段均明显降低;缺血期室性心律失常（VA）出现时间明显推迟且持续时间明显缩短,联合给药组作用更为显著;心律失常发生率明显降低;血浆CK及LDH活力显著降低且联合给药组降低更为显著;梗死面积明显缩小,心肌损伤程度明显减轻,其中联合给药组变化更为显著。结论：雷米普利、BQ-123单用及联合应用均对大鼠在体心肌缺血／再灌注损伤有保护作用,且两药合用在推迟缺血期VA的出现时间,缩短其持续时间,减少CK及LDH漏出,缩小心肌梗死面积方面优于两药各自单用。     

人参皂甙 Rb1与Re对大鼠缺血再灌注心肌细胞凋亡的影响

目的观察人参皂甙Rb1与Re对缺血再灌注心肌细胞凋亡的影响,并比较两者的效应差异.方法结扎Wistar大鼠左冠状动脉前降支,建立大鼠缺血再灌注动物模型;采用透射电镜、缺口末端标记法检测心肌凋亡细胞,利用光学显微镜进行细胞计数.结果 (1)透射电镜发现缺血再灌注组缺血区出现心肌凋亡细胞,假手术组未发现心肌凋亡细胞;(2)缺血再灌注组心肌细胞凋亡数为134.45±45.61个/视野,人参皂甙Rb1治疗组51.65±13.71个/视野,人参皂甙Re治疗组90.66±19.22个/视野,三组间有非常显著性差异(P<0.01).结论心肌缺血再灌注诱导心肌细胞凋亡,人参皂甙Rb1和Re均可显著减少缺血再灌注心肌细胞的凋亡.证实人参皂甙Rb1与Re均有抑制缺血再灌注心肌细胞凋亡,减轻心肌缺血再灌注损伤的作用;人参皂甙Rb1的抗心肌细胞凋亡作用较Re的效果为佳.     

Crystal structure, detonation performance, and thermal stability of a new polynitro cage compound: 2, 4, 6, 8, 10, 12, 13, 14, 15-nonanitro-2, 4, 6, 8, 10, 12, 13, 14, 15-nonaazaheptacyclo [5.5.1.13, 11. 15, 9] pentadecane

A new polynitro cage compound 2, 4, 6, 8, 10, 12, 13, 14, 15-nonanitro-2, 4, 6, 8, 10, 12, 13, 14, 15-nonaazaheptcyclo [5.5.1.1(3,11).1(5,9)] pentadecane (NNNAHP) was designed in the present work. Its molecular structure was optimized at the B3LYP/6-31 G(d,p) level of density functional theory (DFT) and crystal structure was predicted using the Compass and Dreiding force fields and refined by DFT GGA-RPBE method. The obtained crystal structure of NNNAHP belongs to the P-1 space group and the lattice parameters are a = 9.99 ?, b = 10.78 ?, c = 9.99 ?, α = 90.01°, β = 120.01°, γ = 90.00°, and Z = 2, respectively. Based on the optimized crystal structure, the band gap, density of state, thermodynamic properties, infrared spectrum, strain energy, detonation characteristics, and thermal stability were predicted. Calculation results show that NNNAHP has detonation properties close to those of CL-20 and is a high energy density compound with moderate stability.     

Relations of the Al,B, Ba,Br, Ca,Cl, Cu,Fe, K,Li, Mg,Mn, Na,P, S,Si, Sr,and Zn mass fractions to morphometric parameters in pediatric and nonhyperplastic young adult prostate glands

The variation with age of the 18 trace element mass fractions and some histological characteristics of intact prostate glands of 50 subjects aged 0–30 years was investigated by instrumental neutron activation analysis, inductively coupled plasma atomic emission spectrometry, and a quantitative morphometric analysis. Mean values ± standard error of the mean (M ± SΕΜ) for the mass fractions (in milligrams per kilogram wet tissue) of these trace elements in pre-puberty were: Al 28.5 ± 9.0, B 0.40 ± 0.11, Ba 1.48 ± 0.44, Br 10.5 ± 1.5, Ca 241 ± 30, Cl 3,203 ± 278, Cu 3.51 ± 0.89, Fe 33.7 ± 4.1, K 2,364 ± 145, Li 0.020 ± 0.004, Mg 153 ± 23, Mn 0.46 ± 0.06, Na 2,286 ± 130, P 1,391 ± 100, S 1,698 ± 132, Si 62 ± 11, Sr 0.38 ± 0.08, and Zn 27.6 ± 2.3. During puberty and postpuberty, when there is a significant increase in circulating androgens, the mean values were: Al 7.2 ± 1.4, B 0.21 ± 0.05, Ba 0.25 ± 0.06, Br 5.8 ± 1.0, Ca 433 ± 81, Cl 2,314 ± 201, Cu 1.77 ± 0.13, Fe 20.9 ± 1.6, K 2,585 ± 118, Li 0.0088 ± 0.0014, Mg 232 ± 27, Mn 0.34 ± 0.04, Na 1,875 ± 107, P 1,403 ± 98, S 1,673 ± 73, Si 22.2 ± 3.1, Sr 0.22 ± 0.03, and Zn 93.3 ± 8.9. Mean values (M ± SΕΜ) of percent volumes (%) of the stroma, epithelium and lumen in the prostate before puberty were 73.4 ± 2.6, 20.4 ± 1.7, and 4.45 ± 0.94, respectively, versus 46.5 ± 2.5, 38.5 ± 1.9, and 14.9 ± 1.2 during puberty and postpuberty. This work’s results confirm that the Zn mass fraction in prostate tissue is an androgen-dependent parameter. For the first time it has been demonstrated that the glandular lumen is a main pool of Ca, Mg, and Zn accumulation and that the stroma is a main pool of Al, B, Ba, Br, Cl, Cu, Fe, Mn, Na, and Si accumulation in the normal human prostate, for the age range 0–30 years. It was concluded that the Ca, Mg, and Zn binds tightly within the prostatic fluid, because the volume of glandular lumen reflects the volume of prostatic fluid.     

The Effect of Age and Gender on Al, B, Ba, Ca, Cu, Fe, K, Li, Mg, Mn, Na, P, S, Sr, V, and Zn Contents in Rib Bone of Healthy Humans

The effect of age and gender on major, minor, and trace element contents in the intact rib bone of 80 relatively healthy 15–55-year-old women and men was investigated. Contents or upper limit of contents of 16 chemical elements in the rib bone were determined by inductively coupled plasma atomic emission spectrometry (ICP-AES). Mean values (M?±?SΕΜ) for the mass fraction of Ba, Ca, Cu, Fe, K, Li, Mg, Na, P, S, Sr, and Zn (milligram per kilogram of dry bone) were as follows: 2.54?±?0.16, 171,400?±?4,050, 1.35?±?0.22, 140?±?11, 1,874?±?71, 0.049?±?0.011, 2,139?±?38, 5,378?±?88, 75,140?±?1,660, 1,881?±?51, 291?±?20, and 92.8?±?1.5, respectively. The upper limits of contents of Al, B, Mn, and V were <7.20, <0.65, <0.36, and <0.03, respectively. Statistically significant tendency for the Ca, Mg, and P content to decrease with age was found in the human rib bone, regardless of gender. The mass fraction of Fe in the male rib bone increases with age. It was shown that higher Ca, Mg, Na, P, and Sr mass fractions as well as lower Fe content were typical of female ribs as compared to those in male ribs.     

Simultaneous measurement of the trace elements Al, As, B, Be, Cd, Co, Cu, Fe, Li, Mn, Mo, Ni, Rb, Se, Sr, and Zn in human serum and their reference ranges by ICP-MS

The goal of this article was to establish reference ranges of the concentration of trace elements in human serum and to compare these results with those reported by other authors. We describe the sample preparation and measurement conditions that allow the rapid, precise, and accurate determination of Al, As, B, Be, Cd, Co, Cu, Fe, Li, Mn, Mo, Ni, Rb, Se, Sr, and Zn in human serum samples (n=110) by inductively coupled plasma-mass spectrometry (ICP-MS). Accuracy and precision were determined by analyzing three reconstituted reference serum samples by comparison with other methods and by the standard addition procedure. The advantages of the ICP-MS method include short time of analysis of the elements mentioned, low detection limit, high precision, and high accuracy. Disadventages include a high risk of contamination due to the presence of some of the elements of interest in the environment, the relatively delicate sample handling, and the high cost of the equipment.     

Distribution of N,P, K,Ca, Mg,S, Zn,Fe, Mn and Cu in groundnut

Summary Concentration of N, P, K, Ca, Mg and S in summer groundnut crop was higher than in kharif while Zn, Fe, Mn and Cu contents were higher in summer crop. Kernel's N, P and Zn; Leaflet's Ca and Mn; Stem's K and Fe; Root's S and Cu and Petiole's Mg contents were highest. Shell's N, P, K, Mg, S, Zn and Cu; Kernel's Ca, Fe and Mn contents were the least. N, P, K, S, Zn and Cu concentrations decreased linearly as the crop grew. Ca, Mg, Fe and Mn concentrations did not display any distinct pattern. Ca concentration was positively correlated with pod yield in both the seasons.     

Reference values for the concentrations of As,Cd, Co,Cr, Cu,Fe, I,Hg, Mn,Mo, Ni,Pb, Se,and Zn in selected human tissues and body fluids

This report attempts to formulate reference ranges of elemental concentrations for 15 trace elements in selected human tissues and body fluids. A set of samples consisting of whole blood, blood serum, urine, milk, liver, and hair were chosen and considered for 15 elements of biological significance: As, Cd, Co, Cr, Cu, F, Fe, I, Hg, Mn, Mo, Ni, Pb, Se, and Zn. The results represent wholly or partially data received from 40 countries of the global regions of Africa, Asia, Europe, North, South, and Central America, Australia, and New Zealand. This survey, even if qualitative, has been useful in demonstrating certain trends of trace-element scenarios around the world. It is of course recognized that both diet and environment exert a strong influence on the distribution pattern of several elements, such as As, Cd, Mn, Pb, Se, and Zn. A limited comparison of the available information on soil status of different countries reflected some interesting associations for elements, such as Mn and Zn. Importantly, this study revealed that only a few countries were in a position to identify a reasonable amount of data on samples requested for this project. Regretably, for a number of countries, any dependable data for even such essential elements as Cu, Fe, and Zn were not available. In view of the nutritional importance of many elements, the time is ripe for concerted efforts by intergovernmental agencies to initiate investigations or commission task forces/projects to generate reliable reference data for selected global regions, which sadly lack data of any kind at present.     

New Coleoptera records from New Brunswick, Canada: Stenotrachelidae, Oedemeridae, Meloidae, Myceteridae, Boridae, Pythidae, Pyrochroidae, Anthicidae, and Aderidae

We report 19 new species records for the faunal list of Coleoptera in New Brunswick, Canada, six of which are new records for the Maritime provinces, and one of which is new Canadian record. We also provide the first recent records for five additional species in New Brunswick. One new species of Stenotrachelidae, Cephaloon ungulare LeConte, is added to the New Brunswick faunal list. Additional records are provided for Cephaloon lepturides Newman, as well the first recent record of Nematoplus collaris LeConte. Two species of Oedemeridae, Asclera puncticollis (Say) and Asclera ruficollis (Say), are newly reported for New Brunswick, and additional locality and bionomic data are provided for Calopus angustus LeConte and Ditylus caeruleus (Randall). The records of Ditylus caerulus are the first recent records for the province. Three species of Meloidae, Epicauta pestifera Werner, Lytta sayi LeConte, and Meloe augustcollis Say are reported the first time for New Brunswick; Epicauta pestifera is newly recorded in Canada. Lacconotus punctatus LeConte and the family Mycteridaeis newly recorded for New Brunswick. The first recent records of Borus unicolor Say (Boridae) are reported from the province. One new species of Pythidae, Pytho siedlitzi Blair, and the first recent records of Pytho niger Kirby are added to the faunal list of New Brunswick. Three species of Pyrochroidae are newly reported for the province, including Pedilus canaliculatus (LeConte) and Pedilus elegans (Hentz), which are new for the Maritime provinces. Five species of Anthicidae and the first recent record of Anthicus cervinus LaFerté-Sénectére are newly reported for New Brunswick. Anthicus melancholicus LaFerté-Sénectère, Sapintus pubescens (LaFerté-Sénectère), Notoxus bifasciatus (LeConte), and Stereopalpus rufipes Casey are new to the Maritime provinces faunal list. Ambyderus granularis (LeConte) is removed from the faunal list of the province. Three species of Aderidae, Vanonus huronicus Casey, Zonantes fasciatus (Melsheimer), and Zonantes pallidusWerner, are newly recorded for New Brunswick; Zonantes fasciatus and Vanonus huronicus are new for the Maritime provinces' faunal list. Collection data, bionomic data, and distribution maps are presented for all these species.     

Potential Compounds for Oral Cancer Treatment: Resveratrol,Nimbolide, Lovastatin,Bortezomib, Vorinostat,Berberine, Pterostilbene,Deguelin, Andrographolide,and Colchicine

Oral cancer is one of the main causes of cancer-related deaths in South-Asian countries. There are very limited treatment options available for oral cancer. Research endeavors focused on discovery and development of novel therapies for oral cancer, is necessary to control the ever rising oral cancer related mortalities. We mined the large pool of compounds from the publicly available compound databases, to identify potential therapeutic compounds for oral cancer. Over 84 million compounds were screened for the possible anti-cancer activity by custom build SVM classifier. The molecular targets of the predicted anti-cancer compounds were mined from reliable sources like experimental bioassays studies associated with the compound, and from protein-compound interaction databases. Therapeutic compounds from DrugBank, and a list of natural anti-cancer compounds derived from literature mining of published studies, were used for building partial least squares regression model. The regression model thus built, was used for the estimation of oral cancer specific weights based on the molecular targets. These weights were used to compute scores for screening the predicted anti-cancer compounds for their potential to treat oral cancer. The list of potential compounds was annotated with corresponding physicochemical properties, cancer specific bioactivity evidences, and literature evidences. In all, 288 compounds with the potential to treat oral cancer were identified in the current study. The majority of the compounds in this list are natural products, which are well-tolerated and have minimal side-effects compared to the synthetic counterparts. Some of the potential therapeutic compounds identified in the current study are resveratrol, nimbolide, lovastatin, bortezomib, vorinostat, berberine, pterostilbene, deguelin, andrographolide, and colchicine.